

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **160 Health International Limited**

### **健康 160 国际有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2656)**

## **CHANGE OF NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF AUDIT COMMITTEE**

### **CHANGE OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of 160 Health International Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces that Mr. Zhang Ruxie (“**Mr. Zhang**”) has resigned as a non-executive Director and a member of the audit committee under the Board (the “**Audit Committee**”) due to other personal commitments, with effect from March 2, 2026.

Mr. Zhang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and/or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that Mr. Liu Haibin (“**Mr. Liu**”) has been appointed as a non-executive Director and a member of the Audit Committee, with effect from March 2, 2026.

The biographical details of Mr. Liu are as follows:

Mr. Liu Haibin (劉海濱), aged 46, obtained a bachelor's degree in Geology and Mineral Exploration from Jilin University in July 2002. Mr. Liu has over 20 years of experience in internet product development and large-scale platform services, having served hundreds of millions of users. Mr. Liu is currently the Senior Product and Operating Director of the Company and a supervisor of Shenzhen Ningyuan Technology Co., Ltd. (深圳市寧遠科技股份有限公司), a subsidiary of the Company. He served as the key product project manager at Xunlei Limited (a company listed on the NASDAQ, ticker symbol: XNET) before joining the Company.

Since joining the Company in 2015, Mr. Liu has been deeply involved in the internet medical industry for over a decade, leading the research and development of multiple core products and infrastructures, including cloud hospital, doctor-patient IM, big data platform, recommendation algorithm platform and AI products. Mr. Liu has successfully integrated and innovated the cutting-edge technology of internet, product methodology and operational system with the healthcare industry. His achievements are among the best in the industry and have earned him multiple patents.

Mr. Liu has entered into a letter of appointment with the Company for serving as a non-executive Director for a term commencing on March 2, 2026 and ending on the earlier of (i) the completion of three years from the date of his appointment, and (ii) the third annual general meeting of the Company held after the date of his appointment. Mr. Liu's directorship is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. Liu will not receive any fee for his service as a non-executive Director.

As at the date of this announcement, Mr. Liu holds 800,000 outstanding share options under the pre-IPO share option scheme adopted by the Company on August 31, 2023.

Save as disclosed above, as at the date of this announcement, Mr. Liu (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders of the Company; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhang for his contribution to the Company during his tenure, and would like to extend its welcome to Mr. Liu for his new position.

## CHANGE IN COMPOSITION OF AUDIT COMMITTEE

Following the above change of non-executive Director, the Board further announces that the composition of the Audit Committee has changed as follows, with effect from March 2, 2026:

Audit Committee:

Chairman: Mr. Wang Huan

Members: Mr. Liu Haibin, Dr. Xu Weiguo

The chairman and members of the remuneration committee and the nomination committee under the Board remain unchanged.

By order of the Board  
**160 Health International Limited**  
**Mr. LUO Ningzheng**  
*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 2, 2026

*As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.*